Key figures (Sep 2011 - Oct 2017)
Some former students' testimonials
The concept of studying with peers from industry practitioners, regulators and academia is a unique feature of the Eu2P program, which allows me to apply the knowledge seamlessly in my professional works. Highly recommended and appreciated.
I will definitely recommend training programs within the Eu2P platform and I am looking forward to my next course!
Thanks so much for this opportunity, studying at Eu2P is one of the best experiences in my life, it was the training that I needed to get a high-quality education.
I would strongly recommend the Master diploma for those seeking deep knowledge in pharmacovigilance and pharmacoepidemiology
... the Eu2P experience was very positive for me and brought me a solid (and demanding!) training that I think will be highly beneficial to me in the future
I recommend this program for anyone interested in Pharmacovigilance and Pharmacoepidemiology
Organisations trusting us for staff competency development
- Real-life practices inputs from insiders such as the regulatory and industry members of the Eu2P consortium and from international guest experts invited to share experience and interact with students
- Course compliance with the core competencies and knowledge requirements such as WHO-ISoP requirements for pharmacovigilance and ISPE requirements for pharmacoepidemiology and with the imi-train competency profiles in Drug Safety Sciences
- Inclusion of last research and methodologies advances in collaboration with the IMI PROTECT stakeholders
- The full online courses approach to ease professional study-time management has been awarded a trophy for higher education innovation (Educatec-Educatice 2012)
- Modular and time flexible courses comply with lifelong learning and continuing professional development as described by the LifeTrain initiative
- Academic standards and quality of the programme are ensured by the Eu2P Executive Board including academic representatives of the 6 Eu2P degree awarding universities
- Compliance with main quality items of ENQA's report on "Standards and Guidelines for Quality Assurance in the European Higher Education Area"
- Cross quality review of assessments between Eu2P academic partners
- Independent external examination of programme assessments and equity
Recommendations & collaborations
Eu2P training programme is recommended by the ENCePP
as important in building future capacity in the European Union to undertake high quality, scientifically independent research.
IMI PROTECT project and Eu2P foster collaboration in postgraduate training and exchange of trainees between pharmacovigilance and pharmacoepidemiology centres. PROTECT also provides pharmacoepidemiological research findings and new methodology inputs for Eu2P teaching materials and programmes.
Eu2P training programme has been awarded a PharmaTrain Centre Recognition following a quality assessment of its Master Education and Training programme by The PharmaTrain Federation.
IMI EMTRAIN's On-course®, the European portal of biomedical postgraduate education and training resources is indexing Eu2P courses and providing a Eu2P course filter in its Advanced Search feature.
IMI SafeSciMET is collaborating with Eu2P to adapt course modules into blended learning format on the Eu2P eLearning platform under the collaborative framework of the imi-train project.
IMI European platform for education and training in the medical, biomedical and pharmaceutical sciences, imi-train, is promoting Eu2P academic postgraduate programmes as well as CPD training in pharmacovigilance and pharmacoepidemiology.
Publications & media highlights
- Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action.
A. Radecka, L. Loughlin, M. Foy, M. Viana de Ferraz Guimaraes, V. Macolic Sarinic, M. Dimov Di Giusti, M. Lesicar, S. Straus, D. Montero, J. Pallos, J. Ivanovic, J. Raine
Drug Saf (2018).
- What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects.
R. van Eekeren, L. Rolfes, A.S. Koster, L. Magro, G. Parthasarathi, H. Al Ramimmy, T. Schutte, D. Tanaka, E. van Puijenbroek, L. Härmark
Drug Saf (2018).
- 'All this wouldn’t have been possible without IMI' - an interview with Eu2P project coordinators.
IMI JU in Success stories from projects, 01 February 2018.
- Carrying the torch for medical innovation.
IMI JU in IMI Results and Impact, 06 Octobre 2017.
- Risk Communication in a Pharmacovigilance Environment.
Clinical Therapeutics. 39, no. 4 (April 2017): 672–74.
- An Introduction to Pharmacovigilance, 2nd Edition.
P. Waller, and M. Harrison-Woolrych
Wiley-Blackwell, April 2017.
- Practical Implementation in Six Member States.
M. Kaeding, J. Schmälter, C. Klika. in Pharmacovigilance in the European Union : Practical Implementation across Member States, edited by Wiesbaden: Springer, February 2017.
- البرنامج الأوروبي في اليقظة الدوائية: درجة الماجستير في اليقظة الدوائية عن بعد [European programme in pharmacovigilance: distant pharmacovigilance Master programme]
هاجر علي [Hager Ali]
Egypt Scholars blog May, 2017
- From Face-to-Face training to blended learning in the postgraduate program SafeSciMET - a case study.
J.C. Vos, S. Dragovic, M. Jochimsen, J. Dirach, H. Foth, J. Wiese, O.J. Bjerrum
Eur. J. Pharm. Sci., 01 January 2017.
- Opportunities and Challenges for Drug Development: Public–Private Partnerships, Adaptive Designs and Big Data.
O. Yildirim, M. Gottwald, P. Schüler and M.C. Michel
Front. Pharmacol., 06 December 2016.
- Job and Career Opportunities in the Pharmaceutical Sector.
J.R. Thomas, C. van Schravendijk, L. Smit and L. Saso.
In Special Topics in Drug Discovery, edited by T. Chen and S.C. Chai, November 2016.
- Elaboration et évaluation d’un site d’e-learning pour l’apprentissage de la recherche en médecine générale.
N. De Chanaud.
Thèse de Médecine Générale, 27 septembre 2016.
- How can an adaptive training programme support change in organisational strategy?
Intrinsic Activity, 2016; 4 (Suppl. 1): A4.1
- Essential learnings: How do I begin...?
benefit-risk assessment, the blog around structured decision making in medicine, June, 2016
- Shaping Europe's Vision for Personalised Medicine.
The PerMed SRIA (Strategic Research and Innovation Agenda), Jul. 2015.
- Structured Benefit–risk Assessment: A Review of Key Publications and Initiatives on Frameworks and Methodologies.
S. Mt-Isa, M. Ouwens, V. Robert, M. Gebel, A. Schacht, and I. Hirsch.
Pharmaceutical Statistics, May 2015.
- European Initiatives for Better Training in Medicines Development.
Journal of Medicines Development Sciences 1, no. 1 (May 2015).
- Guide de Conception de Formation Ouverte et à Distance (FOAD) Dans Le Monde de La Santé.
Haute Autorité de santé, Apr. 2015.
- The Innovative Medicines Initiative: an engine for regulatory science.
M. Goldman, N. Seigneuret, H.G. Eichler
Nat Rev Drug Discov. 2015 Jan;14(1):1-2.
- Chapter 6 - How Can the Innovative Medicines Initiative Help to Make Medicines Development More Efficient?
In Re-Engineering Clinical Trials, 55–63. Elsevier - Academic Press, Jan. 2015.
- Teaching Pharmacovigilance: The WHO-ISoP Core Elements of a Comprehensive Modular Curriculum.
J. Beckmann, U. Hagemann, P. Bahri, A. Bate, I.W. Boyd, G.J. Dal Pan, B.D. Edwards, et al.
Drug Safety, Aug. 2014, 1–17.
- Practical Experience in Teaching Pharmacovigilance.
S. Evans, and I. Douglas
In Mann's Pharmacovigilance, 805–6. John Wiley & Sons, Ltd, Apr. 2014.
- Eu2P: The First European Online Public–Private Joint Training Program in Pharmacovigilance and Pharmacoepidemiology.
K. Palin, C. Bataille, S. Liège, R. Schimmer, and A. Fourrier-Réglat
In Mann's Pharmacovigilance, 785–92. John Wiley & Sons, Ltd, Apr. 2014.
- Bordeaux : L'Université Se Met Au Numérique.
France 3 Aquitaine. Feb. 2014.
- Towards a Single VOICE for European Clinical Pharmacology: Proposals for Future Developments.
J.K. Aronson and G. Velo.
European Journal of Clinical Pharmacology 69, no. 11 (Nov. 2013): 1981–84.
- La Formation à Distance 'Made in Aquitaine' Qui Intéresse Harvard.
Journal l'Aquitaine, journal d'information du Conseil Régional d'Aquitaine, Sep. 2013.
- Prescrire juste, plutôt que juste prescrire.
M. Molimard, M.-C. Perault-Pochat, C. Funck-Brentano, M. Bardou, R. Bordet, and J.-L. Montastruc.
Le Monde.fr, Apr. 2013.
- Regulatory Science: Researchers in the Pipeline.
Nature 496, no. 7445 (Apr. 2013): 387–89.
- Opening Industry-Academic Partnerships.
Science, Apr. 2013.
- Background Paper 7.4 Pharmacogenetics and Stratified Medicine.
S.J.H. Vijverberg, A.-H. Maitland-van der Zee.
From Priority Medicines for Europe and the World Project "A Public Health Approach to Innovation" by the World Health Organization, Mar. 2013.
- Enseignement : Bordeaux Segalen Tient La Distance.
Sud-Ouest Feb. 2013.
- Continuing Medical Education and Professional Development in the European Union.
H. Silva, F.R. Bühler, B. Maillet, H. Maisonneuve, L.A. Miller, A. Negri, and P.D. Stonier.
Pharmaceutical Medicine 26, no. 4 (Dec. 2012): 223–33.
- Better Comms in Meds.
K. Palin, C. Bataille, S. Liège, E. Swain, A. Fourrier-Réglat, and R. Schimmer.
Public Service Review: Health and Social Care, no. 34 (Dec. 2012): 71.
- TV report on Eu2P programme
Emission Modes d'Emplois.
TV7 Bordeaux, Nov. 2012.
- Pharmacovigilance Medical Writing: A Good Practice Guide
Wiley-Blackwell, July 2012
- Conference Scene: 5th Anniversary Meeting of the European Research Network Pharmacogenetics/Pharmacogenomics.
J.C. Fox, A. Daly, I. Cascorbi, A. Alfirevic, H. Linden, and A.-H. Maitland-van der Zee
Pharmacogenomics Vol. 13, No. 7 (May 2012): 747-749.
- European Initiative towards Quality Standards in Education and Training for Discovery, Development and Use of Medicines.
H. Klech, C. Brooksbank, S. Price, P. Verpillat, F.R. Bühler, D. Dubois, N. Haider, et al.
European Journal of Pharmaceutical Sciences 45, no. 5 (Apr. 2012): 515–20.
- The Innovative Medicines Initiative: A European Response to the Innovation Challenge.
Clinical Pharmacology & Therapeutics 91, no. 3 (Mar. 2012): 418–25.
- Cobert's Manual of Drug Safety and Pharmacovigilance.
Jones & Bartlett Learning 2011.
I have really enjoyed the master programme study with Eu2P on a part-time basis, which allows me to enhance both my theoretical and practical knowledge in pharmacovigilance and epidemiology fields alongside my heavy professional duty as medicine development director. The concept of studying with peers from industry practitioners, regulators and academia is a unique feature of the Eu2P program, which allows me to apply the knowledge seamlessly in my professional works. Highly recommended and appreciated.
I am delighted I came across Eu2P Program offerings. Actually when I came across it I started asking from some previous students testimonials through Linkedin search , and they told me how the program really affected their careers in a positive way, so I decided to start with the “Medicines benefit assessment” training domain and selected the “Methods in clinical research and pharmacoepidemiology and in the assessment of the efficacy of medicine D2M3” training module, as I believe it can give me a wider review of this area and can benefit my career. The training was engaging and deeply related to my work. I liked the further recommended reading topics from different literature sources and I also liked the “WIKI” part as it provided a collaboration space with colleagues and also gave me an option to study my colleagues' points of views regarding the topics studied. As I am a full-time employee it was somehow challenging to keep up with the syllabus in my free time but overall the workload was fine. I will definitely recommend training programs within the Eu2P platform and I am looking forward to my next course!
Thanks so much for this opportunity, studying at Eu2P is one of the best experiences in my life, it was the training that I needed to get a high-quality education. I enjoyed being part of the master program. I have to thank all of the central office collaborators by it. I really recommend to everyone who wants to get a high-quality training in pharmacovigilance and Pharmacoepidemiologic. Thanks.
The Eu2P provided me with unparalleled opportunities to learn from experts in the field as it brought together experts from academia, industry and regulatory agencies. It was an eye-opening experience where it introduced me to the various practices within the field of pharmacoepidemiology and pharmacovigilance. The online format and the great support provided by the instructors and the Eu2P office made it a rewarding experience. I greatly appreciated being able to choose among the six specialisation tracks to choose what fitted my needs. I would strongly recommend the Master diploma for those seeking deep knowledge in pharmacovigilance and pharmacoepidemiology.
I would definitely recommend Eu2P to people looking for basic education and training in pharmacovigilance/pharmacoeconomics and related areas. The programme I followed was very interesting and I learned a lot from it. For a large part, the material on which we worked was derived from real-case situations and case studies, concrete examples and testimonies (including some famous scandals in the healthcare industry). It was very positive that it covered and to some extent tried to integrate the various points of views of the main actors involved in risk communication (regulators, pharma industry, medical professionals and patients). The risk evaluation and communication modules, in particular, provide an opportunity to build a good appreciation of the complexity of how benefits/risks are evaluated in healthcare, and how those risks are perceived by populations – as well as the importance and difficulty to make populations aware of those risks and behave rationally about it. Also, much appreciated were the modules covering pharmacoeconomic aspects. If there is a point which I think could be improved in this programme, it is on the organisational side. It was sometimes difficult to follow all tasks that had to be fulfilled. I think the difficulty is inherent to this ‘distant’ mode of learning, but still, the presentation of the schedules of the courses was at times confusing and I think could be improved in some respects (avoiding conflicting dates and incoherence for example). Another suggestion concerns the therapeutic areas covered in the examples of different modules. There was a too strong focus on cardiovascular diseases and less on diseases with very high medical need (such as cancer) which are prioritised by in the current pharma research landscape. But on the whole, the Eu2P experience was very positive for me and brought me a solid (and demanding!) training that I think will be highly beneficial to me in the future.
Eu2P Master was a great experience, the program is instructed by various professionals from academia, pharmaceutical companies, and regulatory agencies. The program is suited for different needs where you can choose from different specialisations tracks. The learning platform is very easy to use and Eu2P office’s staff team always available for you. I recommend this program for anyone interested in Pharmacovigilance and Pharmacoepidemiology.